PVPedro Henrique Villar-Delfino

Pedro Henrique Villar-Delfino

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pedro Henrique Villar-Delfino has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of the OvarianTag biomarker panel's applicability in detecting Krukenberg tumors.

    by Ana Beatriz Ramos Do Nascimento, Eduardha Santos Temponi Barroso, Anna Carolina Almeida de Paula, Stephanie Braga Gonçalves da Silva, Rafaela L Opes Figueiredo de Andrade, Thalía Rodrigues de Souza Zózimo, Aline Luiza Costa e Silva, Ramon De Alencar Pereira, Pedro Henrique Villar Delfino, Paulo Guilherme De Oliveira Salles, et al.

    Krukenberg tumor is a metastatic ovarian adenocarcinoma, typically originating from the gastrointestinal tract, especially gastric cancer. It accounts for a significant proportion of ovarian tumors, being more common in Asian populations. These tumors usually affect younger women and have a poor prognosis. Diagnosis is challenging due to clinical similarities with other ovarian cancers, requiring a multimodal approach, including imaging tests, histopathological analysis, and biochemical markers. CA-125 may be useful in diagnosis but lacks specificity. Identifying molecular biomarkers specific to Krukenberg tumors could improve diagnosis and treatment. This study investigated the use of the OvarianTag® biomarker panel, developed to assess the prognosis of epithelial ovarian cancer (EOC), to differentiate between primary ovarian cancers and metastatic tumors from other sites, such as those from gastrointestinal origin. The research analyzed Krukenberg tumor samples and primary ovarian cancer samples, utilizing RNA extracted from tumor tissues and gene expression analysis by RT-qPCR. Despite genetic analysis, the OvarianTag® algorithm was unable to distinguish Krukenberg tumors from primary ovarian cancers accurately. The expression of genes TNFSRF10B, TNFSRF10C, and CASP8 showed no significant differences between the groups, and the algorithm failed to classify Krukenberg tumors correctly. These results suggest that OvarianTag® is not effective for this specific application, highlighting the need for new biomarkers to improve the diagnosis of metastatic ovarian tumors.

  • Open Access

    Associations of urinary NGAL with body mass index and waist-to-hip ratio in obesity-related kidney injury

    by Regiane Penaforte Santos, Luciana Ferreira Antunes, Edmarcio Olinto Fonseca, Cláudia Maria Andrade Fernandes Vieira, Mirelli Aparecida Petruceli Almeida, Pedro Henrique Villar-Delfino, José Augusto Nogueira-Machado, Caroline Maria Oliveira Volpe

    The global prevalence of obesity has increased markedly, contributing to morbidities such as cardiovascular disease, type 2 diabetes, and obesity-related kidney disease. Chronic kidney disease (CKD) associated with obesity often progresses silently, making early diagnosis challenging. Traditional markers like the albumin-to-creatinine ratio (ACR) have limitations, highlighting the need for more sensitive biomarkers. Urinary neutrophil gelatinase-associated lipocalin (uNGAL) has emerged as a promising indicator of early renal injury. This study evaluated the uNGAL levels in 90 adult women stratified by body mass index (BMI) and waist-to-hip ratio (WHR) to assess their potential as a biomarker for obesity-associated kidney damage. Anthropometric measurements, including weight, height, waist circumference, and hip circumference, were obtained. Urine samples were analyzed for uNGAL using ELISA. Comparative and correlation analyses explored the associations between uNGAL and anthropometric variables. The results showed significantly higher uNGAL levels in obese participants and those classified as moderate- or high-risk by WHR compared to those in the controls (p < 0.05). Within the obese group, uNGAL correlated positively with BMI (r = 0.60) and weight (r = 0.52), while in the high-risk WHR group, positive correlations were found with weight (r = 0.54) and hip circumference (r = 0.50). These findings suggest that uNGAL may serve as an early, non-invasive biomarker for detecting subclinical kidney stress in women with obesity, particularly those with central adiposity.

  • Open Access

    Drug Repurposing and Artificial Intelligence in Multiple Sclerosis: Emerging Strategies for Precision Therapy

    by Pedro Henrique Villar-Delfino, Paulo Pereira Christo, Caroline Maria Oliveira Volpe

    Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system (CNS) characterized by inflammation, demyelination, axonal degeneration, and gliosis. Its pathophysiology involves a complex interplay of genetic susceptibility, environmental triggers, and immune dysregulation, ultimately leading to progressive neurodegeneration and functional decline. Although significant advances have been made in disease-modifying therapies (DMTs), many patients continue to experience disease progression and unmet therapeutic needs. Drug repurposing—the identification of new indications for existing drugs—has emerged as a promising strategy in MS research, offering a cost-effective and time-efficient alternative to traditional drug development. Several compounds originally developed for other diseases, including immunomodulatory, anti-inflammatory, and neuroprotective agents, are currently under investigation for their efficacy in MS. Repurposed agents, such as selective sphingosine-1-phosphate (S1P) receptor modulators, kinase inhibitors, and metabolic regulators, have demonstrated potential in promoting neuroprotection, modulating immune responses, and supporting remyelination in both preclinical and clinical settings. Simultaneously, artificial intelligence (AI) is transforming drug discovery and precision medicine in MS. Machine learning and deep learning models are being employed to analyze high-dimensional biomedical data, predict drug–target interactions, streamline drug repurposing workflows, and enhance therapeutic candidate selection. By integrating multiomics and neuroimaging data, AI tools facilitate the identification of novel targets and support patient stratification for individualized treatment. This review highlights recent advances in drug repurposing and discovery for MS, with a particular emphasis on the emerging role of AI in accelerating therapeutic innovation and optimizing treatment strategies.


  • Open Access

    Edaravone Inhibits Inflammation in Toll-Like Receptor 4-Stimulated PBMNCs from Multiple Sclerosis Patients

    by Luciana Ferreira Antunes, Regiane Penaforte Santos, Júlia Vieira Carvalho, Paulo Pereira Christo, Pedro Henrique Villar-Delfino, Caroline Maria Oliveira Volpe

    Background: Multiple sclerosis (MS) is a neurological disorder that is directly linked to inflammation in the central nervous system (CNS). The activation of toll-like receptors (TLRs) exacerbates neuroinflammation by increasing the production of reactive oxygen species (ROS) and proinflammatory cytokines. Edaravone (EDV) has been proposed as a potential therapy for CNS diseases because of its free radical scavenging and anti-inflammatory properties. This study investigated the effects of EDV on the inflammatory response in TLR4-stimulated peripheral blood mononuclear cells (PBMNCs) from MS patients and a healthy control group. Methods: The impact of EDV on ROS production in lipopolysaccharide (LPS)-stimulated PBMNCs was assessed using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) reduction and luminol-dependent chemiluminescence assays. The interleukin (IL)-6 concentration in the PBMNC supernatants was measured using enzyme-linked immunosorbent assay (ELISA). Results: The results showed that ROS production in PBMNCs stimulated using LPS (a TLR4 activator) was significantly inhibited (p < 0.05) by EDV in the MS patients and control group. Additionally, EDV significantly reduced IL-6 secretion in TLR4-stimulated PBMNCs in these groups (p < 0.05). No significant differences were observed between the groups. Conclusion: Our findings suggest that EDV may serve as an adjunctive therapy for MS by reducing ROS and IL-6 production in TLR4-stimulated PBMNCs in MS patients, highlighting its potential in modulating neuroinflammation and oxidative stress.


  • Open Access

    Antioxidant effects of resveratrol in granulocytes from multiple sclerosis patients

    by Pedro Henrique Villar-Delfino, Regiane Penaforte Santos, Paulo Pereira Christo, José Augusto Nogueira-Machado, Caroline Maria Oliveira Volpe

    Aim: Neuroinflammation is a characteristic of multiple sclerosis (MS). Resveratrol (RSV) has potent antioxidant properties and has emerged as a promising therapeutic agent for various inflammatory diseases. This study investigated the effects of RSV on inflammatory responses via reactive oxygen species (ROS) production and leukocyte cytokine secretion in patients with MS and healthy controls. Methods: The effects of RSV on ROS production in resting and stimulated granulocytes (in the presence of opsonized particles) were assessed using luminol-dependent chemiluminescence. The cytokines interleukin (IL)-10, IL-1β, IL-6, and high mobility group box 1 (HMGB1) in the supernatant of peripheral blood mononuclear cells (PBMNCs) were quantified using enzyme-linked immunosorbent assay (ELISA). Results: RSV significantly downregulated ROS production in resting and stimulated granulocytes in patients with MS and healthy controls. In the control group, RSV reduced IL-6 levels by 49% in the PBMNC supernatant, whereas IL-6 levels remained unchanged in the MS group. Interestingly, higher levels of IL-10 were detected in PBMNC supernatants from patients with MS than in controls. No significant changes were observed in IL-1β and HMGB1 levels in the PBMNC supernatant. Conclusions: Controlling ROS production is a key target for treating inflammatory diseases. Our findings suggest that RSV can effectively modulate ROS production in MS, highlighting its potential as a promising adjunct therapy for controlling oxidative innate immune responses in MS.


  • IL-6, IL-1β, and MDA Correlate with Thrombolysis in Myocardial Infarction (TIMI) Risk Score in Patients with Acute Coronary Syndrome

    by Marcus Vinícius de Paula da Silva, Pedro Henrique Villar-Delfino, José Augusto Nogueira-Machado, Caroline Maria Oliveira Volpe

    Background: Inflammation plays a significant role in the pathophysiology of Acute Coronary Syndrome (ACS) but is not included in current risk stratification. Objective: To determine the association between Thrombolysis in Myocardial Infarction (TIMI) risk score and inflammatory biomarkers in the ACS, including unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI). We hypothesized that including inflammatory biomarkers could add prognostic value to the TIMI risk score. Methods: In this cross-sectional study, serum levels of interleukins (IL)-6 and IL-1β and MDA (malondialdehyde) were quantified by ELISA and colorimetry, respectively , patients with ACS (n = 48; 31.3% with UA, 33.3% with NSTEMI, and 35.4% with STEMI) and healthy controls (n = 43). We assessed the TIMI scores in the first 24 h after symptom onset. Results: The results showed that patients with ACS had significantly higher levels (p<0.05) of the inflammatory biomarkers IL-6, IL-1β, and MDA compared to the control group. However, we found no significant differences in IL-6, IL-1β, and MDA levels among the patients with ACS according to their classification as UA, NSTEMI, and STEMI. Positive correlations were observed between TIMI and IL-6 (r=0.68), IL-1β (r= 0.53), and MDA (r=0.58) in patients with UA and between TIMI and IL-1β (r= 0.62) in STEMI patients. Conclusion: These data suggest the presence of a pro-inflammatory profile in patients with ACS as well as positive correlations between TIMI scores and the inflammatory biomarkers IL-6, IL-1β, and MDA in patients with UA and between TIMI scores and IL-1β in patients with STEMI. Combining inflammatory biomarkers with the TIMI risk score could provide better insight into the processes involved in ACS.


  • Is Galanin a Promising Therapeutic Resource for Neural and Nonneural Diseases?

    by Caroline Maria Oliveira Volpe, Tatiana Vaz, Fabiana Rocha-Silva, Pedro Henrique Villar-Delfino, José Augusto Nogueira-Machado

    Background: Galanin (GAL) constitutes a family of neuropeptides composed of four peptides: (i) galanin (GAL), (ii) galanin-message associated peptide (GAMP), (iii) galanin-like peptide (GALP), and (iv) alarin. GAL contains 29/30 amino acids, and its biological action occurs through the interactions with its various receptors (GALR1, GALR2, and GALR3). The neuropeptide GAL regulates several physiological and pathophysiological functions in the central nervous system, the peripheral nervous system, and the peripheral organs. GAL is secreted mainly by oligodendrocytes, astrocytes, and the gastrointestinal tract, and its effect depends on the interaction with its different receptors. These receptors are expressed mainly in the central, peripheral nervous systems and the intestines. Objective: The present review evaluates the role of GAL family in inflammatory diseases. An overview is given of the signaling and pharmacological effects due to the interaction between GAL and GALR in different cell types. The potential use of GAL as a therapeutic resource is critically discussed. Conclusion: GAL is suggested to have an anti-inflammatory function in some situations and a proinflammatory function in others. The literature on GAL is controversial and currently not conclusive. This could be due to the complexity of the metabolic network signaling induced by the interactions between GAL and GALR. In the next future, GAL might be a promising therapeutic resource for several diseases, but its practical use for disease control is presently not advisable.


  • Open Access

    Post-fire resprout in an endangered and narrow endemic shrub from rupestrian grasslands, Serra do Cipó, southeastern Brazil

    by Henrique Furst, Ronnie P. Da Silva, G. Wilson Fernandes, Laura Z. Gallupo, Isabel C.A. Machado, Pedro Villar, Daniel Negreiros

    Although there is evidence that the vegetation from rupestrian grasslands is resilient to fire, investigations about the effects of increasing frequency of anthropogenic fires in the rare and endemic plants from this ecosystem are still incipient. In this study, we monitored the post-fire resprouting of the endemic and endangered shrub species Coccoloba cereifera Schwacke (Polygonaceae) from rupestrian grasslands, southeastern Brazil. Five months after the fire 100% of the monitored individuals resprouted. However, one year after the fire, the burned plants had the ramet length 24% lower and number of leaves 53.5% smaller in relation to unburned plants. Burned plants showed a much higher relative growth rate in number of leaves and much lower reproductive investment compared to unburned plants. Although the studied species showed a high ability to resprout after fire, the pattern of vegetative growth and reproductive investment showed by the burned plants suggested that the increasing frequency of anthropogenic fires represents a serious threat to C. cereifera. Keywords: Coccoloba cereifera, conservation, Espinhaço Range, plant growth, reproductive phenology.